Ernexa Therapeutics (ERNAW) Change in Account Payables (2022 - 2026)

Ernexa Therapeutics (ERNAW) has 4 years of Change in Account Payables data on file, last reported at -$500000.0 in Q1 2026.

• Quarterly Change in Account Payables changed N/A year-over-year to -$500000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.3 million (changed N/A YoY) and the FY2025 annual result came in at $750000.0, up 162.24% from the prior year.
• Change in Account Payables improved to -$500000.0 in Q1 2026, from -$559000.0 in the prior quarter.
• In the past five years, Change in Account Payables ranged from a high of $3.4 million in Q3 2022 to a low of -$559000.0 in Q4 2024.
• A 4-year average of -$45363.6 and a median of -$437000.0 in 2022 frame the typical range for Change in Account Payables.
• Annual changes were most pronounced in 2023 — Change in Account Payables plunged 112.91% — and 2024, when it surged 152.05%.
• Tracing ERNAW's Change in Account Payables over 4 years: stood at -$437000.0 in 2022, then changed by 0.0% to -$437000.0 in 2023, then retreated by 27.92% to -$559000.0 in 2024, then grew by 10.55% to -$500000.0 in 2026.
• The last three Change in Account Payables figures came in at -$500000.0 (Q1 2026), -$559000.0 (Q4 2024), and $228000.0 (Q3 2024), per Business Quant data.